Morrow Atkinson III net worth and biography

Morrow III Biography and Net Worth

Director of 89bio

Dr. Atkinson is Executive Vice President and Chief Technical Operations Officer, Vertex Pharmaceuticals, Head of Commercial Manufacturing and Supply Chain of Vertex Pharmaceuticals with over 20 years of experience in biopharmaceutical development, launch, manufacturing and supply chain. Prior to his role at Vertex, Dr. Atkinson served in a number of roles at Bristol Myers Squibb (BMS), including most recently as Senior Vice President of Global Manufacturing Operations, where he helped lead the manufacturing and cell therapy integration team for BMS’s $74 billion merger with Celgene. Prior to BMS, he served as Chief Scientific Officer at Cook Pharmica (now Catalent) and Head of Biologics Development & Manufacturing Sciences at Eli Lilly, where he specialized in biologics, manufacturing and development. Throughout his career, he has participated in the development, commercialization and manufacturing of multiple commercial products at Eli Lilly, BMS and Vertex. He has also been instrumental in spearheading the building and qualification of R&D and commercial manufacturing facilities across the United States and Europe. Dr. Atkinson holds a Ph.D. from Stanford University in Biological Sciences and a B.S. from Indiana University in Biology.

What is Morrow Atkinson III's net worth?: The estimated net worth of Morrow Atkinson III is at least $124,661.46 as of June 12th, 2024. III owns 15,972 shares of 89bio stock worth more than $124,661 as of March 26th. This net worth evaluation does not reflect any other investments that III may own. Learn More about Morrow Atkinson III's net worth.
How do I contact Morrow Atkinson III?: The corporate mailing address for III and other 89bio executives is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. 89bio can also be reached via phone at 415-432-9270 and via email at investors@89bio.com. Learn More on Morrow Atkinson III's contact information.
Has Morrow Atkinson III been buying or selling shares of 89bio?: Morrow Atkinson III has not been actively trading shares of 89bio during the past quarter. Most recently, Edward Morrow Atkinson III sold 6,250 shares of the business's stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $17.91, for a transaction totalling $111,937.50. Learn More on Morrow Atkinson III's trading history.
Who are 89bio's active insiders?: 89bio's insider roster includes Gregory Grunberg (Director), Michael Hayden (Director), Morrow III (Director), Kathleen Laporte (Director), Ryan Martins (CFO), Charles Mcwherter (Director), Rohan Palekar (CEO), Ollin Sykes (Director), and Ram Waisbourd (Insider). Learn More on 89bio's active insiders.
Are insiders buying or selling shares of 89bio?: In the last twelve months, 89bio insiders bought shares 5 times. They purchased a total of 5,744,285 shares worth more than $50,235,693.75. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 10,963 shares worth more than $71,149.87. The most recent insider tranaction occured on January, 30th when Director Ra Capital Management, L.P. bought 5,714,285 shares worth more than $49,999,993.75. Insiders at 89bio own 2.8% of the company. Learn More about insider trades at 89bio.
Information on this page was last updated on 1/30/2025.

Morrow Atkinson III Insider Trading History at 89bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/1/2023	Sell	6,250	$17.91	$111,937.50

Morrow Atkinson III Buying and Selling Activity at 89bio

89bio Company Overview

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Today's Range

Now: $7.81

$7.66

$7.99

50 Day Range

MA: $9.03

$6.09

$11.66

2 Week Range

Now: $7.81

$5.99

$11.84

Volume

578,643 shs

Average Volume

1,182,963 shs

Market Capitalization

$1.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17